Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Retained Earnings (2019 - 2026)

ADC Therapeutics has reported Retained Earnings over the past 8 years, most recently at -$802000.0 for Q1 2026.

  • Quarterly results put Retained Earnings at -$802000.0 for Q1 2026, up 99.95% from a year ago — trailing twelve months through Mar 2026 was -$802000.0 (up 99.95% YoY), and the annual figure for FY2025 was -$1.6 billion, down 115026.04%.
  • Retained Earnings reached -$802000.0 in Q1 2026 per ADCT's latest filing, up from -$1.6 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$802000.0 in Q1 2026 and bottomed at -$1.6 billion in Q4 2025.
  • Median Retained Earnings over the past 5 years was -$1.2 billion (2023), compared with a mean of -$1.1 billion.
  • The largest annual shift saw Retained Earnings crashed 115026.04% in 2025 before it surged 99.95% in 2026.
  • Over 5 years, Retained Earnings stood at -$872.8 million in 2022, then plummeted by 53.01% to -$1.3 billion in 2023, then surged by 99.89% to -$1.4 million in 2024, then plummeted by 115026.04% to -$1.6 billion in 2025, then skyrocketed by 99.95% to -$802000.0 in 2026.
  • Business Quant data shows Retained Earnings for ADCT at -$802000.0 in Q1 2026, -$1.6 billion in Q4 2025, and -$1.6 billion in Q3 2025.